Publication: 3389

Publication: 3389

Prognostic value of clinical treatment score post-5 years (CTS5) and late relapse risk in hormone receptor-positive HER2-positive breast cancer in the North Central Cancer treatment group (NCCTG) N9831 (Alliance) and NSABP-B31 (NRG) trials

DOI

URL

Google Scholar

Citation:: Cancer Res vol 81 (4 Supplement) PS6-03

Meeting Instance:: SABCS 2020
Year:: 2020
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3906

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: Genentech
Grants:: U10CA180821, BCRF-19-161, U10CA180868 and U10CA180822 (NRG)

Corr. Author:
Authors:: Tanmayi Pai Angelica Gil Yaohua Ma Zhuo Li Pooja Advani Alvaro Moreno-Aspitia Gerardo Colon-Otero Edith A. Perez Yan Asmann Katherine Pogue-Geile E.A. Thompson Saranya Chumsri

Networks:: LAPS-MN026, NY021, PR028

Study
Multiple Studies, or Legacy Studies in Alliance Study:: NCCTG-N9831, NSABP B-31
Phases:: 3

Keywords: